2024 FDA/CTSI-CN Boot Camp
The FDA Boot Camp is a unique, hybrid immersion experience at the FDA that provides selected fellows with structured training and guidance from FDA experts in the practice of regulatory science. Over the course of the Boot Camp, fellows take part in FDA meetings, join multidisciplinary teams of regulatory scientists, and work with FDA experts to complete a capstone project.
This unique opportunity — developed as a partnership between the FDA and CTSI-CN, provides Children’s National fellows with a six-month immersion experience at the FDA. Over the course of the Boot Camp, fellows take part in FDA meetings, join multidisciplinary teams of regulatory scientists, and work with FDA experts to complete a capstone project.
Program Information
- Eligibility - The first Boot Camp is open to all Children’s National fellows with active appointments as of July - December 2024. Applicants must also attend at least one of the upcoming pre-Bootcamp sessions (information below).
- Format - The boot camp consists of longitudinal rotations, with one-week sessions per month at the FDA for 6 months (6 sessions). This format is flexible.
- Selection Process - Applications will be due in January 2024. The one (1) fellow selected for the first Boot Camp will be selected in February 2024.
- Program Dates - Boot Camp will take place from July - December 2024.
Upcoming Pre-Boot Camp Sessions
Before the application window opens, the FDA will hold a series of four pre-Boot Camp sessions in November 2023, open to the Children’s National research community. FDA staff will present on topics directly related to the Boot Camp. Anyone interested in applying for the boot camp must attend at least one of these sessions
| Session 1 | Session 2 | Session 3 | Session 4 |
|---|---|---|---|
| November 13, 2023 4:00 - 5:00 pm |
November 15, 2023 4:00 - 5:00 pm |
November 28, 2023 4:00 - 5:00 pm |
November 29, 2023 4:00 - 5:00 pm |
| Building a Study: FDA Perspective | Building an Investigational New Drug Application: FDA Perspective | Drug Safety Assessment: FDA Perspective | Good Clinical Practice Principles in the Conduct of Clinical Trials: FDA Perspective |
